Clinical Trial Update: A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial of MRG007 (ARR-217) in patients with advanced solid tumors is recruiting, evaluating safety and initial efficacy signals in colorectal, gastric,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer
• Pancreatic Cancer

Drugs mentioned

• MRG007 (ARR-217)

Snippet

Sponsor: ArriVent BioPharma, Inc. | Conditions: Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer | Phase 1 | Status: RECRUITING